Sign in
4

Changes in Ownership

Jade Biosciences, Inc. Filed Acc 0001415889-23-006376

CHIEF SCIENTIFIC OFFICER sold 2,250 shares at an average $18.20 ($40,942)

  • CHIEF SCIENTIFIC OFFICER acquired 2,250 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

NIVEN RALPH · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2023-04-05 Exercise or conversion : show line 1 in the form +650 $1.74 $1,131 2,259 D
2023-04-05 Exercise or conversion : show line 2 in the form +1,600 $2.14 $3,424 3,859 D
2023-04-05 Sale : show line 3 in the form −1,715 $17.91 $30,721 2,144 D
2023-04-05 Sale : show line 4 in the form −535 $19.11 $10,221 1,609 D
Open-market sales · 2,250 sh · avg $18.20 · $40,942

Table II: Derivative

5 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2023-04-05 Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) −450 $1.74 2030-09-03 450 20,058 D
2023-04-05 Exercise or conversion : show line 6 in the form Stock Option (Right to Buy) −200 $1.74 2030-09-03 200 12,688 D
2023-04-05 Exercise or conversion : show line 7 in the form Stock Option (Right to Buy) −200 $2.14 2031-04-01 200 14,494 D
2023-04-05 Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) −650 $2.14 2031-04-01 650 44,058 D
2023-04-05 Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) −750 $2.14 2031-04-01 750 52,982 D
Loading xslF345X04/form4-04072023_060401.xml…